Lv64
2850 积分 2025-04-12 加入
Tebentafusp: First Approval
1个月前
已完结
Could IL-25 be a potential therapeutic target for intestinal inflammatory diseases?
1个月前
已完结
First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity
2个月前
已完结
Nociceptor-derived CGRP enhances dermal type I conventional dendritic cell function to drive autoreactive CD8+ T cell responses in vitiligo
2个月前
已完结
UB-221, an antibody that neutralizes IgE and downregulates the CD23 receptor: a potential treatment for the alpha-gal syndrome
2个月前
已完结
Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC)
3个月前
已完结
An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases
4个月前
已完结
Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody–Drug Conjugate Payloads
4个月前
已完结
Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate
4个月前
已完结
Discovery of a new anti-γc antibody in clinical development for the treatment of autoimmune diseases
4个月前
已完结
皖公网安备34019202002308
